242 related articles for article (PubMed ID: 1398913)
1. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
3. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
5. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
[TBL] [Abstract][Full Text] [Related]
6. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
7. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
[TBL] [Abstract][Full Text] [Related]
8. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
10. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
11. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
12. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
14. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.
Chu C; Schneerson R; Robbins JB; Rastogi SC
Infect Immun; 1983 Apr; 40(1):245-56. PubMed ID: 6601061
[TBL] [Abstract][Full Text] [Related]
15. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
16. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
17. Designer vaccines to prevent infections due to group B Streptococcus.
Kasper DL
Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
[TBL] [Abstract][Full Text] [Related]
18. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines.
Brigtsen AK; Kasper DL; Baker CJ; Jennings HJ; Guttormsen HK
J Infect Dis; 2002 May; 185(9):1277-84. PubMed ID: 12001045
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
[TBL] [Abstract][Full Text] [Related]
20. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
